biotech / news / / Malayala Manorama
Eli Lilly is testing an obesity drug that helps patients lose 28% weight.
Eli Lilly's retatrutide helped patients lose an average of 28.3% of their weight over 80 weeks.
KEY POINTS
- More than 45% of retatrutide trial participants lost at least 30% of their weight.
- Late-stage trial data show reduced reports of dysesthesia compared to earlier safety data.
- Retatrutide's weight loss efficacy now approaches levels historically associated with bariatric surgery.
- Eli Lilly plans to launch retatrutide, targeting various obesity stages, next year.
COMPANIES
Summarized by Newsio from Malayala Manorama. How we summarize →